2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients

Annals of Oncology

Volumn 27, Issue , 2016, Pages v119-v133

  Roila, F ^a   Molassiotis, A ^b   Herrstedt, J ^c   Aapro, M ^d   Gralla, R J ^e   Bruera, E ^f   Clark Snow, R A ^g   Dupuis, L L ^h   Einhorn, L H ⁱ   Feyer, P ^j   Hesketh, P J ^k   Jordan, K ^l   Olver, I ^m   Rapoport, B L ⁿ   Roscoe, J ^o   Ruhlmann, C H ^c   Walsh, D ^p   Warr, D ^q   van der Wetering, M ^r   on behalf of the participants of the MASCC/ESMO Consensus Conference Copenhagen, ^s  

^a S MARIA HOSPITAL   (Italy)

^b HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d CLINIQUE DE GENOLIER   (Switzerland)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ INDIANA UNIVERSITY   (United States)

^j Neukoelln ^*  (Germany)

^k Lahey Health Cancer Institute   (United States)

^l MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^m UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

ⁿ Medical Oncology Centre of Rosebank   (South Africa)

^o UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^p Our Lady's Hospice Ltd Dublin   (Ireland)

^q PRINCESS MARGARET HOSPITAL   (Canada)

^r EMMA CHILDREN S HOSPITAL   (Netherlands)

^s ESMO HEAD OFFICE   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOLASETRON MESILATE; FOSAPREPITANT; GRANISETRON; NETUPITANT; OLANZAPINE; OPIATE; OXALIPLATIN; PALONOSETRON; ROLAPITANT; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ACUTE DISEASE; ADVANCED CANCER; ANTICIPATORY NAUSEA AND VOMITING; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CHEMORADIOTHERAPY; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC DISEASE; CONSENSUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; INTESTINE CANCER; INTESTINE OBSTRUCTION; NAUSEA AND VOMITING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION INJURY; RADIOTHERAPY INDUCED NAUSEA AND VOMITING; RISK MANAGEMENT; RISK REDUCTION; TREATMENT RESPONSE;

EID: 84995772540     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw270     Document Type: Article

References (68)

1. Roila F, Herrstedt J, Aapro M et al. Guideline update for MASCC and ESMO In the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21(Suppl. 5): v232-v243.
2. Grunberg SM, Osoba D, Hesketh PJ et al. Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity-an update. Support Care Cancer 2005; 13: 80-84.
3. Jordan K, Jahn F, Aapro M. Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review. Ann Oncol 2015; 26: 1081-1090.
4. Grunberg S, Chua D, Maru A et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 2011; 29: 1495-1501.
5. Saito H, Yoshizawa H, Yoshimori K et al. Efficacy and safety of single-dose fosaprepitant in the prevention of chemotherapy-induced nausea and vomiting in patients receiving high-dose cisplatin: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Ann Oncol 2013; 24: 1067-1073.
6. Hu Z, Cheng Y, Zhang H et al. Aprepitant triple therapy for the prevention of chemotherapy-induced nausea and vomiting following high-dose cisplatin in Chinese patients: a randomized, double-blind, placebo-controlled phase III trial. Support Care Cancer 2014; 22: 979-987.
7. Hesketh PJ, Rossi G, Rizzi G et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized doseranging pivotal study. Ann Oncol 2014; 25: 1340-1346.
8. 1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC). Support Care Cancer 2015; 23: 3281-3288.
9. Rapoport BL, Chasen MR, Gridelli C et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol 2015; 16: 1079-1089.
10. Roila F, Ruggeri B, Ballatori E et al. Aprepitant versus metoclopramide, both combined with dexamethasone, for the prevention of cisplatin-induced delayed emesis: a randomized, double-blind study. Ann Oncol 2015; 26: 1248-1253.
11. Aapro M, Rugo H, Rossi G et al. A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy. Ann Oncol 2014; 25: 1328-1333.
12. Schwartzberg LS, Modiano MR, Rapoport BL et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 1071-1078.
13. Roila F, Ruggeri B, Ballatori E et al. Aprepitant versus dexamethasone for preventing chemotherapy-induced delayed emesis in patients with breast cancer: arandomized double-blind study. J Clin Oncol 2014; 32: 101-106.
14. Saito M, Aogi K, Sekine I et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10: 115-124.
15. Brygger L, Herrstedt J. 5-hydroxytryptamine3 receptor antagonists and cardiac side effects. Expert Opin Drug Saf 2014; 13: 1407-1422.
16. Boccia RV, Gordan LN, Clark G et al. Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study. Support Care Cancer 2011; 19: 1609-1617.
17. Karthaus M, Tibor C, Lorusso V et al. Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemotherapy (HEC). Support Care Cancer 2015; 23: 2917-2923.
18. Boccia R, Grunberg S, Franco-Gonzales E et al. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial. Support Care Cancer 2013; 21: 1453-1460.
19. Van Laere K, De Hoon J, Bormans G et al. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging. Clin Pharmacol Ther 2012; 92: 243-250.
20. Navari RM, Gray SE, Kerr AC. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. J Support Oncol 2011; 9: 188-195.
21. Abe M, Hirashima Y, Kasamatsu Y et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phase II trial. Support Care Cancer 2016; 24: 675-682.
22. Navari RM, Qin R, Ruddy KJ et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving highly emetogenic chemotherapy (HEC): Alliance A221301, a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2015; 33 (Suppl. 29S): abstr 176.
23. Popovic M, Warr DG, Deangelis C et al. Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 2014; 22: 1685-1697.
24. The Italian Group for Antiemetic Research. Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 2000; 342: 1554-1559.
25. Inoue A, Yamada Y, Matsumura Y et al. Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer 2003; 11: 528-532.
26. Hesketh PJ, Bosnjak SM, Nikolic V, Rapoport B. Incidence of delayed nausea and vomiting in patients with colorectal cancer receiving irinotecan-based chemotherapy. Support Care Cancer 2011; 19: 2063-2066.
27. Rapoport BL, Jordan K, Boice JA et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, doubleblind study. Support Care Cancer 2010; 18: 423-431.
28. Weinstein C, Jordan K, Green SA et al. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. Ann Oncol 2016; 27: 172-178.
29. Hesketh PJ, Schnadig ID, Schwartzberg LS et al. Efficacy of the neurokinin-1 receptor antagonist rolapitant in preventing nausea and vomiting in patients receiving carboplatin-based chemotherapy. Cancer 2016; 122: 2418-2425.
30. Tanioka M, Kitao A, Matsumoto K et al. A randomized, placebo controlled, doubleblind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. Br J Cancer 2013; 109: 859-865.
31. Yahata H, Kobayashi H, Sonoda K et al. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin. Int J Clin Oncol 2016; 21: 491-497.
32. Ito Y, Karayama M, Inui N et al. Aprepitant In patients with advanced non-small-cell lung cancer receiving carboplatin-based chemotherapy. Lung Cancer 2014; 84: 259-264.
33. Hesketh PJ, Wright O, Rosati G et al. Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. Support Care Cancer 2012; 20: 1471-1478.
34. Nishimura J, Satoh T, Fukunaga M et al. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial. Eur J Cancer 2015; 51: 1274-1282.
35. Albany C, Brames MJ, Fausel C et al. Randomized, double-blind, placebo-controlled phase III crossover study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5 day-cisplatin combination chemotherapy regimens: a Hoosier Oncology Group (HOG) study. J Clin Oncol 2012; 30: 3998-4003.
36. Olver IN, Grimison P, Chatfield M et al. Results of a 7-day aprepitant schedule for the prevention of nausea and vomiting in a 5-day cisplatin-based germ cell tumor chemotherapy. Support Care Cancer 2013; 21: 1561-1568.
37. Hamada S, Hinotsu S, Kawai K et al. Antiemetic efficacy and safety of a combination of palonosetron, aprepitant and dexamethasone in patients with testicular germ cell tumor receiving 5-day cisplatin-based combination chemotherapy. Support Care Cancer 2014; 22: 2161-2166.
38. Keat CH, Phua G, Abdul Kassim MS et al. Can granisetron injection used as primary prophylaxis improve the control of nausea and vomiting with low-emetogenic chemotherapy? Asian Pac J Cancer Prev 2013; 14: 469-473.
39. Fabi A, Barduagni M, Lauro S et al. Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 2003; 11: 156-161.
40. Molassiotis A, Saunders MP, Valle J et al. A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 2008; 16: 201-208.
41. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 2013; 21: 1655-1663.
42. Chanthawong S, Subongkot S, Sookprasert A. Effective of olanzapine for the treatment of breakthrough chemotherapy-induced nausea and vomiting. J Med Assoc Thai 2014; 97: 349-355.
43. Sigsgaard T, Herrstedt J, Handberg J et al. Ondansetron plus metopimazine compared with ondansetron plus metopimazine plus prednisolone as antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy. J Clin Oncol 2001; 19: 2091-2097.
44. Chan A, Kim HK, Hsieh RK et al. Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice-a longitudinal analysis. Support Care Cancer 2015; 23: 283-291.
45. Molassiotis A, Lee PH, Burke TA et al. Anticipatory nausea, risk factors and its impact on chemotherapy-related nausea and vomiting: results from the Pan European Emesis Registry study. J Pain Symptom Manage 2016; 51: 987-993.
46. Kamen C, Tejani MA, Chandwani K et al. Anticipatory nausea and vomiting due to chemotherapy. Eur J Pharmacol 2014; 722: 172-179.
47. Molassiotis A, Aapro M, Dicato M et al. Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study. J Pain Symptom Manage 2014; 47: 839-848.
48. Dupuis LL, Robinson PD, Boodhan S et al. Guideline for the prevention and treatment of anticipatory nausea and vomiting due to chemotherapy in pediatric cancer patients. Pediatr Blood Cancer 2014; 61: 1506-1512.
49. Pielichowski W, Barzal J, Gawronski K et al. A triple-drug combination to prevent nausea and vomiting following BEAM chemotherapy before autologous hematopoietic stem cell transplantation. Transplant Proc 2011; 43: 3107-3110.
50. Bechtel T, McBride A, Crawford B et al. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. Support Care Cancer 2014; 22: 2911-2916.
51. Stiff PJ, Fox-Geiman MP, Kiley K et al. Prevention of nausea and vomiting associated with stem cell transplant: results of a prospective, randomized trial of aprepitant used with highly emetogenic preparative regimens. Biol Blood Marrow Transplant 2013; 19: 49-55.
52. Schmitt T, Goldschmidt H, Neben K et al. Aprepitant, granisetron, and dexamethasone for prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan in autologous transplantation for multiple myeloma: results of a randomized, placebo-controlled phase III trial. J Clin Oncol 2014; 32: 3413-3420.
53. Enblom A, Bergius Axelsson B, Steineck G et al. One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 2009; 17: 23-32.
54. The Italian Group for Antiemetic Research in Radiotherapy. Radiation-induced emesis: a prospective observational multicenter Italian trial. Int J Radiat Oncol Biol Phys 1999; 44: 619-625.
55. Maranzano E, De Angelis V, Pergolizzi S et al. A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 2010; 94: 36-41.
56. Salvo N, Doble B, Khan L et al. Prophylaxis of radiation-induced nausea and vomiting using 5-hydroxytryptamine-3 serotonin receptor antagonists: a systematic review of randomized trials. Int J Radiat Oncol Biol Phys 2012; 82: 408-417.
57. 3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies. J Radiat Oncol 2013; 2: 271-284.
58. Ruhlmann CH, Christensen TB, Dohn LH et al. Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Oncol 2016; 17: 509-518.
59. Bakhshi S, Batra A, Biswas B et al. Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double-blind, placebo-controlled trial. Support Care Cancer 2015; 23: 3229-3237.
60. Kang H, Loftus S, Taylor A et al. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomised, double-blind, phase 3 trial. Lancet Oncol 2015; 16: 385-394.
61. Gupta M, Davis M, LeGrand S et al. Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol. J Support Oncol, 2013; 11: 8-13.
62. Bruera ED, MacEachern TJ, Spachynski KA et al. Comparison of the efficacy, safety, and pharmacokinetics of controlled release and immediate release metoclopramide for the management of chronic nausea in patients with advanced cancer. Cancer 1994; 74: 3204-3211.
63. Bruera E, Belzile M, Neumann C et al. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage 2000; 19: 427-435.
64. Currow DC, Quinn S, Agar M et al. Double-blind, placebo controlled, randomized trial of octreotide in malignant bowel obstruction. J Pain Symptom Manage 2015; 49: 814-821.
65. Peng X, Wang P, Li S et al. Randomized clinical trial comparing octreotide and scopolamine butylbromide in symptom control of patients with inoperable bowel obstruction due to advanced ovarian cancer. World J Surg Oncol 2015; 13: 50 doi: 10.1186/s12957-015-0455-3.
66. Laval G, Rousselot H, Toussaint-Martel S et al. SALTO: a randomized, multicenter study assessing octreotide LAR in inoperable bowel obstruction. Bull Cancer 2012; 99: E1-E9.
67. Mariani P, Blumberg J, Landau A et al. Symptomatic treatment with lanreotide microparticles in inoperable bowel obstruction resulting from peritoneal carcinomatosis: a randomized, double-blind, placebo-controlled phase III Study. J Clin Oncol 2012; 30: 4337-4343.
68. Laugsand EA, Kaasa S, Klepstad P. Management of opioid-induced nausea and vomiting in cancer patients: systematic review and evidence-based recommendations. Palliat Med 2011; 25: 442-453.